Valneva SE (VALN) Non-Current Deferred Tax Liability (2020 - 2026)
Valneva SE's (VALN) quarterly Non-Current Deferred Tax Liability came in at $5.2 million in Q1 2026, up 19.33% year-on-year from $4.3 million in Q1 2025, and up 1.05% quarter-over-quarter from $5.1 million in Q4 2025.
Valneva SE (VALN) Non-Current Deferred Tax Liability (2020 - 2026) Analysis & Trends
Valneva SE has disclosed Non-Current Deferred Tax Liability across 7 years of filings, most recently posting $5.2 million for Q1 2026.
- Non-Current Deferred Tax Liability for Q1 2026 came in at $5.2 million, up 19.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.2 million (up 19.33% YoY), and the FY2025 annual result was $5.1 million, up 15.4% from the prior year.
- Non-Current Deferred Tax Liability came in at $5.2 million for Q1 2026 at Valneva SE, up from $5.1 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $6.8 million in Q4 2023 to a low of $708051.7 in Q4 2022.
- The 5-year median for Non-Current Deferred Tax Liability is $4.0 million (2024), against an average of $3.4 million.
- Peak annual rise in Non-Current Deferred Tax Liability reached 867.06% in 2023, while the deepest fall reached 49.9% in 2023.
- Valneva SE's Non-Current Deferred Tax Liability stood at $708051.7 in 2022, then jumped by 867.06% to $6.8 million in 2023, then tumbled by 35.05% to $4.4 million in 2024, then increased by 15.4% to $5.1 million in 2025, then rose by 1.05% to $5.2 million in 2026.
- The last three Non-Current Deferred Tax Liability figures came in at $5.2 million (Q1 2026), $5.1 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.19 Mn |
| Mar 31, 2026 | 5.19 Mn |
| Dec 31, 2025 | 5.13 Mn |
| Dec 31, 2025 | 5.13 Mn |
| Sep 30, 2025 | 4.62 Mn |
| Sep 30, 2025 | 4.62 Mn |
| Jun 30, 2025 | 4.57 Mn |
| Jun 30, 2025 | 4.57 Mn |
| Mar 31, 2025 | 4.35 Mn |
| Mar 31, 2025 | 4.35 Mn |
| Dec 31, 2024 | 4.45 Mn |
| Dec 31, 2024 | 4.45 Mn |
| Sep 30, 2024 | 4.16 Mn |
| Sep 30, 2024 | 4.16 Mn |
| Jun 30, 2024 | 4.03 Mn |
| Jun 30, 2024 | 4.03 Mn |
| Mar 31, 2024 | 4.02 Mn |
| Mar 31, 2024 | 4.02 Mn |
| Dec 31, 2023 | 6.85 Mn |
| Dec 31, 2023 | 6.85 Mn |